Comparing genetically engineered mouse mammary cancer models with human breast cancer by expression profiling

Breast Disease

Volumn 28, Issue , 2007, Pages 39-51

  Green, Jeffrey E ^a   Shoushtari, Alexander N ^a   Michalowska, Aleksandra M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; MYC PROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ANIMAL MODEL; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CLASSIFICATION; CANCER GROWTH; CANCER MODEL; CANCER THERAPY; CLINICAL EFFECTIVENESS; CONCEPTUAL FRAMEWORK; CORRELATION ANALYSIS; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE TARGETING; GENETIC ENGINEERING; GENETIC HETEROGENEITY; GENETIC MANIPULATION; GENETIC TRANSCRIPTION; GENOMICS; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IN VIVO STUDY; METASTASIS; MOLECULAR GENETICS; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT RESPONSE;

EID: 36549078221     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/bd-2007-28105     Document Type: Review

References (106)

1. Cancer Facts & Figures 2007. In. Atlanta: American Cancer Society; 2007.
2. D.A. Berry, K.A. Cronin, S.K. Plevritis et al., Effect of screening and adjuvant therapy on mortality from breast cancer, N Engl J Med 353(17) (2005), 1784-1792.
3. P. Eifel, J.A. Axelson, J. Costa et al., National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 13, 2000, J Natl Cancer Inst 93(13) (2001), 979-989.
4. E.O. Hanrahan, V. Valero, A.M. Gonzalez-Angulo and G.N. Hortobagyi, Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): A review ofthe literature, J Clin Oncol 24(13) (2006), 2113-2122.
5. C.M. Perou, S.S. Jeffrey, M. van de Rijn et al., Distinctive gene expression patterns in human mammary epithelial cells and breast cancers, Proc Natl Acad Sci USA 96(16) (1999), 9212-9217.
6. C.M. Perou, T. Sorlie, M.B. Eisen et al., Molecular portraits of human breast tumours, Nature 406(6797) (2000), 747-752.
7. T. Sorlie, C.M. Perou, R. Tibshirani et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci USA 98(19) (2001), 10869-10874.
8. R.D. Cardiff, M.R. Anver, B.A. Gusterson et al., The mammary pathology of genetically engineered mice: The consensus report and recommendations from the Annapolis meeting, Oncogene 19(8) (2000), 968-988.
9. J. Blancato, B. Singh, A. Liu, D.J. Liao and R.B. Dickson, Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses, Br J Cancer 90(8) (2004), 1612-1619.
10. S.L. Deming, S.J. Nass, R.B. Dickson and B.J. Trock, C-myc amplification in breast cancer: A meta-analysis of its occurrence and prognostic relevance, Br J Cancer 83(12) (2000), 1688-1695.
11. C.M. Schlotter, U. Vogt, U. Bosse, B. Mersch and K. Wassmann, C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer, Breast Cancer Res 5(2) (2003), R30-R36.
12. A.M. Brown, Wnt signaling in breast cancer: Have we come full circle? Breast Cancer Res 3(6) (2001), 351-355.
13. S.Y. Lin, W. Xia, J.C. Wang et al., Beta-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression, Proc Natl Acad Sci USA 97(8) (2000), 4262-4266.
14. A. Klinakis, M. Szabolcs, K. Politi, H. Kiaris, S. Artavanis-Tsakonas and A. Efstratiadis, Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice, Proc Natl Acad Sci USA 103(24) (2006), 9262-9267.
15. K. Politi, N. Feirt and J. Kitajewski, Notch in mammary gland development and breast cancer, Semin Cancer Biol 14(5) (2004), 341-347.
16. S. Weijzen, P. Rizzo, M. Braid et al., Activation of Notch-1 signaling maintains the neoplastic phenotype in human Rastransformed cells, Nat Med 8(9) (2002), 979-986.
17. M. Reedijk, S. Odorcic, L. Chang et al., High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival, Cancer Res 65(18) (2005), 8530-8537.
18. J. Bartkova, J. Lukas, M. Strauss and J. Bartek, The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas, Int J Cancer 58(4) (1994), 568-573.
19. M.F. Buckley, K.J. Sweeney, J.A. Hamilton et al., Expression and amplification of cyclin genes in human breast cancer, Oncogene 8(8) (1993), 2127-2133.
20. C. Gillett, V. Fantl, R. Smith et al., Amplification and overexpression of cyclin D1 in breast cancer detected by immuno-histochemical staining, Cancer Res 54(7) (1994), 1812-1817.
21. M.S. Berger, G.W. Locher, S. Saurer et al., Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading, Cancer Res 48(5) (1988), 1238-1243.
22. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich and W.L. McGuire, Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science 235(4785) (1987), 177-182.
23. G.J. Clark and C.J. Der, Aberrant function of the Ras signal transduction pathway in human breast cancer, Breast Cancer Res Treat 35(1) (1995), 133-144.
24. F.C. von Lintig, A.D. Dreilinger, N.M. Varki, A.M. Wallace, D.E. Casteel and G.R. Boss, Ras activation in human breast cancer, Breast Cancer Res Treat 62(1) (2000), 51-62.
25. D.F. Easton, D. Ford and D.T. Bishop, Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium, Am J Hum Genet 56(1) (1995), 265-271.
26. D. Ford, D.F. Easton, M. Stratton et al., Genetic heterogeneity and penetrance analysis ofthe BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium, Am J Hum Genet 62(3) (1998), 676-689.
27. S.R. Lakhani, J. Jacquemier, J.P. Sloane et al., Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations, J Natl Cancer Inst 90(15) (1998), 1138-1145.
28. J. Geradts and P.A. Wilson, High frequency of aberrant p 16(INK4A) expression in human breast cancer, Am J Pathol 149(1) (1996), 15-20.
29. C.J. Sherr and F. McCormick, The RB and p53 pathways in cancer, Cancer Cell 2(2) (2002), 103-112.
30. R.A. Weinberg, The retinoblastoma protein and cell cycle control, Cell 81(3) (1995), 323-330.
31. M.S. Greenblatt, W.P. Bennett, M. Hollstein and C.C. Harris, Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis, Cancer Res 54(18) (1994), 4855-4878.
32. J.M. Nigro, S.J. Baker, A.C. Preisinger et al., Mutations in the p53 gene occur in diverse human tumour types, Nature 342(6250) (1989), 705-708.
33. P.D. Pharoah, N.E. Day and C. Caldas, Somatic mutations in the p53 gene and prognosis in breast cancer: A meta-analysis, Br J Cancer 80 12) (1999), 1968-1973.
34. R. Mazars, L. Spinardi, M. BenCheikh, J. Simony-Lafontaine, P. Jeanteur and C. Theillet, p53 mutations occur in aggressive breast cancer, Cancer Res 52(14) (1992), 3918-3923.
35. R.D. Cardiff, D. Moghanaki and R.A. Jensen, Genetically engineered mouse models of mammary intraepithelial neoplasia, J Mammary Gland Biol Neoplasia 5(4) (2000), 421-437.
36. Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group, Lancet 352(9132) (1998), 930-942.
37. L.J. van 't Veer, H. Dai, M.J. van de Vijver et al., Gene expression profiling predicts clinical outcome of breast cancer, Nature 415(6871) (2002), 530-536.
38. C.A. Hudis and C.T. Dang, Adjuvant therapy for breast cancer: Practical lessons from the early breast cancer trialists' collaborative group, Breast Dis 21 (2004), 3-13.
39. T. Sorlie, R. Tibshirani, J. Parker et al., Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc Natl Acad Sci USA 100(14) (2003), 8418-8423.
40. T. Sorlie, Y. Wang, C. Xiao et al., Distinct molecular mechanisms underlying clinically relevant subtypes ofbreast cancer: Gene expression analyses across three different platforms, BMC Genomics 7 (2006), 127.
41. B. Weigelt, Z. Hu, X. He et al., Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer, Cancer Res 65(20) (2005), 9155-9158.
42. M.L. Asselin-Labat, K.D. Sutherland, H. Barker et al., Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation, Nat Cell Biol 9(2) (2007), 201-209.
43. H. Kouros-Mehr, E.M. Slorach, M.D. Sternlicht and Z. Werb, GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland, Cell 127(5) (2006), 1041-1055.
44. H. Li, P. Cherukuri, N. Li et al., Nestin is expressed in the basal/ myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors, Cancer Res 67(2) (2007), 501-510.
45. R. Rouzier, C.M. Perou, W.F. Symmans et al., Breast cancer molecular subtypes respond differently to preoperative chemotherapy, Clin Cancer Res 11(16) (2005), 5678-5685.
46. L.A. Carey, E.C. Dees, L. Sawyer et al., The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes, Clin Cancer Res 13(8) (2007), 2329-2334.
47. M.J. van de Vijver, L.J. He YD, van't Veer et al., A gene-expression signature as a predictor of survival in breast cancer, N Engl J Med 347(25) (2002), 1999-2009.
48. M. Buyse, S. Loi, L. van't Veer et al., Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer, J Natl Cancer Inst 98(17) (2006), 1183-1192.
49. H.F. Dvorak, Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing, N Engl J Med 315(26) (1986), 1650-1659.
50. H.Y. Chang, J.B. Sneddon, A.A. Alizadeh et al., Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds, PLoS Biol 2(2) (2004), E7.
51. H.Y. Chang, D.S. Nuyten, J.B. Sneddon et al., Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival, Proc Natl Acad Sci USA 102 10) (2005), 3738-3743.
52. A.S. Adler, M. Lin, H. Horlings, D.S. Nuyten, M.J. van de Vijver and H.Y. Chang, Genetic regulators of large-scale transcriptional signatures in cancer, Nat Genet 38(4) (2006), 421-430.
53. L.H. Saal, P. Johansson, K. Holm et al., Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PLEN tumor suppressor pathway activity, Proc Natl Acad Sci USA 104(18) (2007), 7564-7569.
54. S. Paik, S. Shak, G. Tang et al., A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N Engl J Med 351(27) (2004), 2817-2826.
55. X.J. Ma, Z. Wang, P.D. Ryan et al., A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen, Cancer Cell 5(6) (2004), 607-616.
56. C. Fan, D.S. Oh, L. Wessels et al., Concordance among gene-expression-based predictors for breast cancer, N Engl J Med 355(6) (2006), 560-569.
57. L. Ein-Dor, O. Zukand E. Domany, Thousands ofsamples are needed to generate a robust gene list for predicting outcome in cancer, Proc Natl Acad Sci USA 103(15) (2006), 5923-5928.
58. R. Liu, X. Wang, G.Y. Chen et al., The prognostic role of a gene signature from turnorigenic breast-cancer cells, N Engl J Med 356(3) (2007), 217-226.
59. K.V. Desai, N. Xiao, W. Wang et al., Initiating oncogenic event determines gene-expression patterns of human breast cancer models, Proc Natl Acad Sci USA 99(10) (2002), 6967-6972.
60. K. Ellwood-Yen, T.G. Graeber, J. Wongvipat et al., Myc-driven murine prostate cancer shares molecular features with human prostate tumors, Cancer Cell 4(3) (2003), 223-238.
61. M. van Lohuizen, S. Verbeek, B. Scheijen, E. Wientjens, H. van der Gulden and A. Berns, Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging, Cell 65(5) (1991), 737-752.
62. W.W. He, P.J. Sciavolino, J. Wing et al., A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer, Genomics 43(1) (1997), 69-77.
63. P. Kaposi-Novak, J.S. Lee, L. Gomez-Quiroz, C. Coulouarn, V.M. Factor and S.S. Thorgeirsson, Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype, J Clin Invest 116(6) (2006), 1582-1595.
64. P.C. Ma, G. Maulik, J. Christensen and R. Salgia, c-Met: Structure, functions and potential for therapeutic inhibition, Cancer Metastasis Rev 22(4) (2003), 309-325.
65. A. Sweet-Cordero, S. Mukherjee, A. Subramanian et al., An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis, Nat Genet 37(1) (2005), 48-55.
66. J.I. Herschkowitz, K. Simin, V.J. Weigman et al., Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors, Genome Biol 8(5) (2007), R76.
67. Y. Li, B. Welm, K. Podsypanina et al., Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells, Proc Natl Acad Sci USA 100 26) (2003), 15853-15858.
68. C. Lindvall, N.C. Evans, C.R. Zylstra, Y. Li, C.M. Alexander and B.O. Williams, The Win signaling receptor Lrp5 is required for mammary ductal stem cell activity and Wnt1-induced tumorigenesis, J Biol Chem 281(46) (2006), 35081-35087.
69. T. Reya, A.W. Duncan, L. Ailles et al., A role for Wnt signalling in self-renewal of haernatopoietic stem cells, Nature 423(6938) (2003), 409-414.
70. K.K. Deeb, A.M. Michalowska, C.Y. Yoon et al., Identification of an Integrated SV40 T/t-antigen Cancer Signature in Aggressive Human Carcinomas With Poor Prognosis. Submitted.
71. D. Ahuja, M.T. Saenz-Robles and J.M. Pipas, SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation, Oncogene 24(52) (2005), 7729-7745.
72. S. Mousses, L. Bubendorf, U. Wagner et al., Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays, Cancer Res 62(5) (2002), 1256-1260.
73. T.M. Williams and M.P. Lisanti, Caveolin-1 in oncogenic transformation, cancer, and metastasis, Am J Physiol Cell Physiol 288(3) (2005), C494-C506.
74. G.V. Glinsky, O. Berezovska and A.B. Glinskii, Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer, J Clin Invest 115(6) (2005), 1503-1521.
75. L.A. Boyer, K. Plath, J. Zeitlinger et al., Polycomb complexes repress developmental regulators in murine embryonic stem cells, Nature 441(7091) (2006), 349-353.
76. J. Lessard and G. Sauvageau, Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells, Nature 423(6937) (2003), 255-260.
77. A.V. Molofsky, R. Pardal, T. Iwashita, I.K. Park, M.F. Clarke and S.J. Morrison, Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation, Nature 425(6961) (2003), 962-967.
78. I.K. Park, D. Qian, M. Kiel et al., Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells, Nature 423 6937) (2003), 302-305.
79. X.J. Ma, R. Salunga, J.T. Tuggle et al., Gene expression profiles ofhuman breast cancer progression, Proc Natl Acad Sci USA 100 10) (2003), 5974-5979.
80. Y. Ye, T.H. Qiu, C. Kavanaugh and J.E. Green, Molecular mechanisms of breast cancer progression: Lessons from mouse mammary cancer models and gene expression profiling, Breast Dis 19 (2004), 69-82.
81. M. Bacac, P. Provero, N. Mayran, J.C. Stehle, C. Fusco and I. Stamenkovic, A mouse stromal response to tumor invasion predicts prostate and breast cancer patient survival, PLoS ONE 1 (2006), e32.
82. T. Lifsted, T. Le Voyer, M. Williams et al., Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression, Int J Cancer 77(4) (1998), 640-644.
83. T.H. Qiu, G.V. Chandramouli, K.W. Hunter, N.W. Alkharouf, J.E. Green and E.T. Liu, Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: Correlation to human disease, Cancer Res 64(17) (2004), 5973-5981.
84. S. Ramaswamy, K.N. Ross, E.S. Lander and T.R. Golub, A molecular signature of metastasis in primary solid tumors, Nat Genet 33 1) (2003), 49-54.
85. K.W. Hunter, K.W. Broman, T.L. Voyer et al., Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1, Cancer Res 61(24) (2001), 8866-8872.
86. Y.G. Park, X. Zhao, F. Lesueur et al., Sipal is a candidate for underlying the metastasis efficiency modifier locus Mtes1, Nat Genet 37(10) (2005), 1055-1062.
87. N.P. Crawford, A. Ziogas, D.J. Peel, J. Hess, H. Anton-Culver and K.W. Hunter, Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer, Breast Cancer Res 8(2) (2006), R16.
88. M.A. Christophorou, D. Martin-Zanca, L. Soucek et al., Temporal dissection of p53 function in vitro and in vivo, Nat Genet 37(7) (2005), 718-726.
89. D. Ewald, M. Li, S. Efrat et al., Time-sensitive reversal of hyperplasia, in transgenic mice expressing SV40 T antigen, Science 273(5280) (1996), 1384-1386.
90. E.J. Gunther, G.K. Belka, G.B. Wertheim et al., A novel doxycycline- inducible system for the transgenic analysis of mammary gland biology, Faseb J 16(3) (2002), 283-292.
91. L. Hennighausen, R.J. Wall, U. Tillmann, M. Li and P.A. Furth, Conditional gene expression in secretory tissues and skin of transgenic mice using the MMTV-LTR and the tetracycline responsive system, J Cell Biochem 59(4) (1995), 463-472.
92. S.E. Moody, C.J. Sarkisian, K.T. Hahn et al., Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis, Cancer Cell 2(6) (2002), 451-461.
93. A. Ventura, D.G. Kirsch, M.E. McLaughlin et al., Restoration of p53 function leads to tumour regression in vivo, Nature 445 7128) (2007), 661-665.
94. W. Xue, L. Zender C. Miething et al., Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas, Nature 445(7128) (2007), 656-660.
95. C.M. D'Cruz, E.J. Gunther, R.B. Boxer et al., c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations, Nat Med 7(2) (2001), 235-239.
96. E.J. Gunther, S.E. Moody, G.K. Belka et al., Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis, Genes Dev 17(4) (2003), 488-501.
97. R.B. Boxer, J.W. Jang, L. Sintasath and L.A. Chodosh, Lack of sustained regression ofc-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation, Cancer Cell 6(6) (2004), 577-586.
98. S.E. Moody, D. Perez, T.C. Pan et al., The transcriptional repressor Snail promotes mammary tumor recurrence, Cancer Cell 8(3) (2005), 197-209.
99. J.W. Jang, R.B. Boxer and L.A. Chodosh, Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary turnorigenesis, Mol Cell Biol 26(21) (2006), 8109-8121.
100. A.H. Bild, G. Yao, J.T. Chang et al., Oncogenic pathway signatures in human cancers as a guide to targeted therapies, Nature 439 7074) (2006), 353-357.
101. P. Bertheau, E. Turpin, D.S. Rickman et al., Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin-Cyclophosphamide Regimen, PLoS Med 4(3) (2007), e90.
102. A. Potti, H.K. Dressman, A. Bild et al., Genomic signatures to guide the use of chemotherapeutics, Nat Med 12(11) (2006), 1294-1300.
103. H. Hieronymus, J. Lamb, K.N. Ross et al., Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators, Cancer Cell 10(4) (2006), 321-330.
104. J. Lamb, F.D. Crawford, D. Peck et al., The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease, Science 313(5795) (2006), 1929-1935.
105. G. Wei, D. Twomey, J. Lamb et al., Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance, Cancer Cell 10(4) (2006), 331-342.
106. K. Stegmaier J.S. Wong, K.N. Ross et al., Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma, PLoSMed 4(4) (2007), e122.